RxDoctor Payments Data

Katja Austin

Family · Denver, CONPI 1538309687

Payments from drug & device makers

$2,512in general payments, 2019–2025

Across 107 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$282
  • AbbVie$270
  • USWM, LLC$266
  • Indivior Inc.$208
  • Amgen$163
  • Braeburn Inc.$153
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$2,48799%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,512 in reported general payments places this provider in the 90th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$13,166
Medicare patients
32
Services billed
303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$26,251
RelistorMethylnaltrexone Bromide11$25,737
EliquisApixaban20$16,790
TrulicityDulaglutide11$15,218
ButransBuprenorphine20$11,532
MyrbetriqMirabegron15$8,914
FarxigaDapagliflozin Propanediol13$7,598
SymbicortBudesonide/Formoterol Fumarate12$5,233
Buprenorphine22$4,785
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl37$3,904
Duloxetine Hcl24$1,903
Albuterol Sulfate HfaAlbuterol Sulfate42$1,814
Tramadol Hcl ErTramadol Hcl21$1,763
Oxycodone Hcl69$1,117
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$117$25,73711 claims
PfizerEliquis$96$16,79020 claims
Lilly USA, LLCTrulicity, Olanzapine$81$15,70826 claims
AstraZenecaFarxiga, Symbicort$50$12,83125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,182 family providers in Colorado.

Other family in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →